ViraMASC
(I'm getting awfully forgetful, so just catching
up on some filing)
Adenoviral Gene Therapy Vectors - Improved by the Application of ViraMASC Technology
Sue Marlow, Valentis
ASM Conference on
Viral Gene Vectors:
Molecular Biology, Design &
Application to Gene Therapy
April 26 - 29, 2001
Banff, Alberta, Canada
.................................
December 13, 2000
BURLINGAME, Calif. and OXFORD, England /PRNewswire via COMTEX/ -- Valentis, Inc.'s wholly-owned subsidiary, PolyMASC Pharmaceuticals plc, and Oxford BioMedica today announced a collaborative agreement to develop a new version of MetXia, Oxford BioMedica's cancer drug, that will be designed to selectively target tumors following systemic administration of the product. The new version of MetXia will be developed by adding polyethylene glycol (PEG) chains to the drug using PolyMASC's proprietary viraMASC PEGylation technology. Financial terms of the collaboration were not disclosed.
....................................................
21st April 1999
London, UK. Wednesday 21st April, 1999 -- PolyMASC Pharmaceuticals plc (AIM: PCP) today announces a new licence agreement with Onyx Pharmaceuticals Inc., (Nasdaq: ONXX) to allow for the further development of Onyx's genetically modified adenoviruses using PolyMASC's proprietary ViraMASC™ technology. The licence agreement triggers an upfront payment. In addition, further development milestone payments and royalties on future product sales, are payable for each licensed product developed.
Onyx’s lead product, ONYX-015, is a genetically modified adenovirus that efficiently replicates in and kills tumour cells deficient in p53 tumour suppressor function, which occurs in the majority of all human cancers. ONYX-015 is in phase II clinical development. The previous research collaboration between the two companies has shown that in laboratory studies ONYX-015 can be PEGylated using ViraMASC™ technology to maintain infectivity.
......................................................
PolyMASC Pharmaceuticals plc was incorporated in 1995 to commercialize the intellectual property generated by the scientific research team at the Molecular Cell Pathology Laboratory of the Royal Free Hospital School of Medicine, University of London. |
